← 返回

Survivin/BIRC5 衍生肽破坏 survivin 二聚化和细胞分裂并诱导多方面的抗癌效应

英文原题:Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects.

查看英文原题

Survivin/BIRC5-derived peptide disrupts survivin dimerization and cell division and induces multifaceted anti-cancer effects.

PubMed 2026/01/03(内容时间) Mol Ther Oncol Q1 · IF 8.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

Survivin是一种同源二聚体蛋白,在几乎所有癌症中过表达,而在非增殖的成体组织中基本缺失。它是细胞稳态的多功能调节因子,在增殖、凋亡和免疫调节中发挥关键作用,这些过程对癌症的发生和进展至关重要。利用由SMAC/Diablo相互作用蛋白序列组成的肽阵列,我们在survivin中鉴定出一个SMAC结合序列。

在此,我们报道了一种24个氨基酸肽的表征,该肽涵盖survivin的关键结构域:同源二聚体界面、微管、核输入和染色体乘客复合体结合位点。该肽与survivin结合并干扰其二聚化,破坏其与自身及伙伴蛋白(如微管蛋白)的相互作用。当将其工程化为靶向细胞质、线粒体或细胞核的稳定化细胞穿透肽时,它们有效抑制增殖、破坏有丝分裂的完成并诱导凋亡。在肺部肿瘤模型中,这些肽减少了肿瘤细胞增殖和生长,同时激活抗肿瘤免疫应答。它们增加了CD8+ T细胞和NK细胞浸润,并提高了肿瘤中PD-1/PD-L1的表达。

此外,在体外和体内模型中,它们降低了survivin、SMAC和微管蛋白的水平,同时增加了p53表达。这些发现凸显了一种利用survivin衍生工程化肽靶向不可成药的survivin的新策略,在癌症中具有有前景的治疗潜力。

展开英文摘要原文

Survivin, a homodimeric protein overexpressed in virtually all cancers, is largely absent in non-proliferating adult tissues. It is a multifunctional regulator of cellular homeostasis that plays critical roles in proliferation, apoptosis, and immune regulation, which are central to cancer development and progression. Using a peptide array composed of sequences from SMAC/Diablo-interacting proteins, we identified a SMAC-binding sequence within survivin.

Here, we report the characterization of a 24-amino-acid peptide spanning key survivin domains: the homodimer interface, microtubule, nuclear import, and chromosomal passenger complex binding sites. The peptide binds survivin and interferes with its dimerization, disrupting interactions with itself and partner proteins such as tubulin.

When engineered as stabilized cell-penetrating peptides targeted to the cytosol, mitochondria, or nucleus, they effectively inhibited proliferation, disrupted the completion of mitosis, and induced apoptosis. In lung tumor models, the peptides reduced tumor cell proliferation and growth, while activating anti-tumor immune responses. They increased CD8 + T cell and NK cell infiltration and elevated PD-1/PD-L1 expression in the tumors.

Additionally, they reduced the levels of survivin, SMAC, and tubulin, while increasing p53 expression in both in vitro and in vivo models.

These findings highlight a novel strategy for targeting undruggable survivin using survivin-derived engineered peptides, offering promising therapeutic potential in cancer.

论文信息

作者
Santhanam M、Babu V、Shteinfer-Kuzmine A、Pandey SK、Gheber L、Raday G、Shoshan-Barmatz V
单位
Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.Israel
期刊
Molecular therapy. Oncology2026 Mar 19
原文标识
PubMed 41624406 · DOI 10.1016/j.omton.2025.201123